Skip to main content
SpringerLink
Log in

Pharmacogénétique de l’infliximab dans la maladie de Crohn

Pharmacogenetics of infliximab in crohn’s disease

  • Published:
Acta Endoscopica

Résumé

Les études réalisées dans le domaine de la pharmacogénétique contribueront sans aucun doute à une meilleure gestion thérapeutique des maladies inflammatoires intestinales. L’infliximab est actuellement le médicament le plus efficace actuellement dans le traitement des formes réfractaires et fistulisantes de la maladie de Crohn. Cependant, environ un tiers des patients ne répondent pas à ce traitement. A l’heure actuelle, plusieurs études ont été réalisées afin d’identifier des facteurs prédictifs de la réponse à l’infliximab dans la maladie de Crohn. Cette revue résume les connaissances actuelles quant à l’utilisation de l’infliximab dans la maladie de Crohn et fait le point sur les résultats des études réalisées, et plus particulièrement sur les aspects pharmacogénétiques.

Summary

Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn’s disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease, results of a British twin study. BMJ 1996; 312: 95–96.

    PubMed  CAS  Google Scholar 

  2. Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn’s disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990–96.

    Article  PubMed  CAS  Google Scholar 

  3. Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet 2001; 357: 1925–28.

    Article  PubMed  CAS  Google Scholar 

  4. Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel J-F, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001; 411: 599–603.

    Article  PubMed  CAS  Google Scholar 

  5. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar J-P, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001; 411: 603–6.

    Article  PubMed  CAS  Google Scholar 

  6. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn’s disease, the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.

    Article  PubMed  CAS  Google Scholar 

  7. Van den Brande J, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol Suppl 2005; 74: 26–30.

    PubMed  Google Scholar 

  8. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S-I, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha]. Gastroenterology 2005; 128: 376–92.

    Article  PubMed  CAS  Google Scholar 

  9. Lugering A, Schmidt M, Lugering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab Induces Apoptosis in Monocytes From Patients With Chronic Active Crohn’s Disease by Using a Caspase-Dependent Pathway. Gastroenterology 2001; 121: 1145–57.

    Article  PubMed  CAS  Google Scholar 

  10. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002; 50: 206–11.

    Article  PubMed  Google Scholar 

  11. Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation; A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn’s Disease. J Immunol 2006; 176: 2617–24.

    PubMed  CAS  Google Scholar 

  12. Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250–9.

    Article  PubMed  CAS  Google Scholar 

  13. Targan SR HS, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 9: 1029–35.

    Article  Google Scholar 

  14. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the Treatment of Fistulas in Patients with Crohn’s Disease. N Engl J Med 1999; 340: 1398–1405.

    Article  PubMed  CAS  Google Scholar 

  15. Rutgeerts P DHG, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L VHR, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999; 117: 761–9.

    Article  PubMed  CAS  Google Scholar 

  16. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab Maintenance Therapy for Fistulizing Crohn’s Disease. N Engl J Med 2004; 350: 876–85.

    Article  PubMed  CAS  Google Scholar 

  17. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601–8.

    Article  PubMed  CAS  Google Scholar 

  18. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor {alpha}-Neutralizing Agent. N Engl J Med 2001; 345: 1098–1104.

    Article  PubMed  CAS  Google Scholar 

  19. Colombel J-F, Loftus J, Edward V., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn’s disease, The Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19–31.

    Article  PubMed  CAS  Google Scholar 

  20. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor [alpha] treatment in Crohn’s disease, a prospective cohort study. Gastroenterology 2003; 125: 32–9.

    Article  PubMed  CAS  Google Scholar 

  21. Parsi MA, Achkar J-P, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn’s disease. Gastroenterology 2002; 123: 707–13.

    Article  PubMed  CAS  Google Scholar 

  22. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C. Infliximab in the treatment of Crohn’s disease. Predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577–83.

    Article  PubMed  CAS  Google Scholar 

  23. Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharm Ther 2003; 17: 1451–7.

    Article  CAS  Google Scholar 

  24. Vermeire S, Louis E, Carbonez A, Assche G, Noman M, Belaiche J, Vos M, Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D’Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. The American Journal of Gastroenterology 2002; 97: 2357–63.

    Article  PubMed  CAS  Google Scholar 

  25. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and “On Demand” Therapy with Infliximab in Crohn’s Disease. Clinical Experience with 400 Infusions. The American Journal of Gastroenterology 2003; 98: 608–12.

    PubMed  CAS  Google Scholar 

  26. Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharm Ther 2003; 18: 425–31.

    Article  CAS  Google Scholar 

  27. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn’s Disease. Am J Gastroenterol 2006; 101: 1030–8.

    Article  PubMed  Google Scholar 

  28. Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM, Perez-Pariente JM, Lopez-Vazquez A, Francisco R, Rodrigo L. High serum tumor necrosis factor-alpha, levels are associated with lack of response to infliximab in fistulizing Crohn’s disease. Am J Gastroenterol 2002; 97: 2350–6.

    PubMed  CAS  Google Scholar 

  29. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D’Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn disease, association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818–24.

    Article  PubMed  CAS  Google Scholar 

  30. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn’s Disease. Gastroenterology 2001; 120: 1347–55.

    Article  PubMed  CAS  Google Scholar 

  31. Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Bours V. Lymphotoxin alpha gene in Crohn’s disease patients, absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics 2006; 16: 369–73.

    PubMed  CAS  Google Scholar 

  32. Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn’s disease treated with infliximab. Pharmacogenomics J 2002; 2: 127–36.

    Article  PubMed  CAS  Google Scholar 

  33. Dideberg V, Theatre E, Farnir F, Vermeire S, Rutgeerts P, De Vos M, Belaiche J, Franchimont D, Van Gossum A, Louis E, Bours V. The TNF/ADAM 17 system, implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn’s Disease. Pharmacogenet Genomics 2006 (in press).

  34. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P. Tumour necrosis factor-alpha, receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharm Ther 2004; 20: 303–10.

    Article  CAS  Google Scholar 

  35. Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, Olson A, Bao W, Folsch UR, Schreiber S. Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene, an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509–15.

    Article  PubMed  CAS  Google Scholar 

  36. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R. NOD2/CARD15 does not influence response to infliximab in Crohn’s disease. Gastroenterology 2002; 123: 106–11.

    Article  PubMed  CAS  Google Scholar 

  37. Urcelay E, Mendoza JL, Martinez A, Fernandez L, Taxonera C, Diaz-Rubio M, de la Concha EG. IBD5 polymorphisms in inflammatory bowel disease, association with response to infliximab. World J Gastroenterol 2005; 11: 1187–92.

    PubMed  CAS  Google Scholar 

  38. Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel J-F, Watier H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharm Ther 2004; 19: 511–19.

    Article  CAS  Google Scholar 

  39. Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E, Siddiqui MA, Scott LJ, Mascheretti S, Schreiber S, Chaudhary R, Ghosh S, Efthimiou P, Markenson JA, van den Brande J, Hommes DW, Peppelenbosch MP, Sandborn WJ, Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F, McNamara DA, Brophy S, Hyland JM, Su C, Lichtenstein GR, D’Haens G, Hlavaty T. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn’s disease. Pharmacogenet Genomics 2006; 16: 37–42.

    Article  PubMed  CAS  Google Scholar 

  40. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, Schuerbeek N, Noman M, Rutgeerts P, Vermeire S. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharm Ther 2005; 22: 613–26.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Vinciane Dideberg

    Present address: Departments of Human Genetics, University of Liège, Belgium

  2. V. Bours

    Present address: Centre de Génétique Humaine, CHU Sart-Tilman, B35, University of Liège, 4000, Liège, Belgique

Authors and Affiliations

  1. Departments of Human Genetics, University of Liège, Belgium

    V. Bours

  2. Departments of Gastroenterology, CHU Liège and Center for Biomedical Integrated Genoproteomics, University of Liège, Belgium

    E. Louis

Authors
  1. Vinciane Dideberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Louis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Bours
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Dideberg, V., Louis, E. & Bours, V. Pharmacogénétique de l’infliximab dans la maladie de Crohn. Acta Endosc 37, 521–530 (2007). https://doi.org/10.1007/BF02961799

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02961799

Mots-clés

Key-words

Search

Navigation